

DISHMAN PHARMACEUTICALS AND CHEMICALS LIMITED

Bhadr-Raj Chambers, Swastik Cross Roads, Navrangpura, Ahmedabad-380 009

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2010

(Rupees in Lacs)

| Sr. No. | PARTICULARS | STANDALONE | | | CONSOLIDATED | | |
|-----------|---|----------------------------------|--|-------------------------------|----------------------------------|--|-------------------------------|
| | | For the quarter ended 30-06-2010 | Corresponding 3 months ended in the previous year 30-06-2009 | For the Year ended 31-03-2010 | For the quarter ended 30-06-2010 | Corresponding 3 months ended in the previous year 30-06-2009 | For the Year ended 31-03-2010 |
| | | Unaudited | Unaudited | Audited | Unaudited | Unaudited | Audited |
| 1 | a) Net Sales/Income From Operations | 7,101.43 | 7,343.71 | 35,260.88 | 20,188.42 | 22,771.47 | 91,535.74 |
| | b) Other Operating Income | 19.35 | 22.59 | 315.28 | 1,038.52 | 1,548.38 | 2,693.46 |
| | c) Income from Associates | - | - | - | 0.38 | (0.01) | 4.91 |
| | Total Income (a+b+c) | 7,120.78 | 7,366.29 | 35,576.16 | 21,227.32 | 24,319.84 | 94,234.11 |
| 2 | Expenditure | | | | | | |
| | a) (Increase)/Decrease in Stock in trade and work in progress | (517.72) | 47.64 | 1,287.47 | (620.91) | (505.91) | 700.99 |
| | b) Consumption of Raw Materials | 3,206.56 | 2,417.19 | 12,280.46 | 6,069.41 | 5,953.60 | 23,177.78 |
| | c) Purchase of traded goods | 10.73 | 58.60 | 246.97 | 140.20 | 165.16 | 3,796.36 |
| | d) Employees Cost | 907.33 | 820.74 | 3,371.31 | 6,314.23 | 7,402.74 | 25,405.80 |
| | e) Depreciation | 653.64 | 529.76 | 2,064.10 | 1,610.38 | 1,452.52 | 5,941.60 |
| | f) Other Expenditure | 1,269.55 | 1,615.46 | 6,347.98 | 3,839.12 | 4,435.20 | 18,077.06 |
| | g) Total | 5,530.09 | 5,489.39 | 25,598.29 | 17,352.43 | 18,903.31 | 77,099.59 |
| 3 | Profit from Operations before Other Income, Interest and Exceptional Items (1-2) | 1,590.69 | 1,876.90 | 9,977.87 | 3,874.89 | 5,416.53 | 17,134.52 |
| 4 | Other Income | - | - | - | - | - | - |
| 5 | Profit before Interest and Exceptional Items (3+4) | 1,590.69 | 1,876.90 | 9,977.87 | 3,874.89 | 5,416.53 | 17,134.52 |
| 6 | Interest & Financial Charges (Net) | 530.26 | 522.71 | 2,037.18 | 820.32 | 1,035.26 | 3,876.73 |
| 7 | Profit after Interest but before Exceptional Items (5-6) | 1,060.44 | 1,354.19 | 7,940.69 | 3,054.57 | 4,381.27 | 13,257.79 |
| 8 | Exceptional Items | - | - | - | - | - | - |
| 9 | Profit (+)/ Loss (-) from Ordinary Activities before tax (7+8) | 1,060.44 | 1,354.19 | 7,940.69 | 3,054.57 | 4,381.27 | 13,257.79 |
| 10 | Tax expense | 111.16 | 95.00 | 903.82 | 340.66 | 460.65 | 1,495.25 |
| | - Current Tax | 58.93 | 92.55 | 217.47 | 171.78 | 92.64 | 342.70 |
| | - Deferred | 52.24 | 1.20 | 683.25 | 168.88 | 366.76 | 1,149.45 |
| | - Wealth | - | 1.25 | 3.10 | - | 1.25 | 3.10 |
| 11 | Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10) | 949.27 | 1,259.19 | 7,036.87 | 2,713.91 | 3,920.62 | 11,762.54 |
| 12 | a) Extraordinary Items (net of tax expense Rs.____) | - | - | - | - | - | - |
| | b) Prior Period Expenses | (11.18) | 5.46 | (110.00) | (11.08) | 5.49 | (171.68) |
| | c) Short provision of Income Tax | - | - | 39.52 | - | - | 196.72 |
| 13 | Net Profit (+)/ Loss (-) for the period (11-12) | 960.45 | 1,253.73 | 7,107.35 | 2,724.99 | 3,915.13 | 11,737.50 |
| 14 | Paid-up Equity Share Capital (Face Value of Rs 2/- per equity share) | 1,613.94 | 1,613.94 | 1,613.94 | 1,613.94 | 1,613.94 | 1,613.94 |
| 15 | Reserves Excluding Revaluation Reserves as per balance sheet of previous accounting year | - | - | 59,507.70 | - | - | 75,480.04 |
| 16 | Basic and Diluted EPS (before & after Extraordinary Items) | - | - | - | - | - | - |
| | Basic EPS (in Rs.Not annualised) | 1.19 | 1.56 | 8.81 | 3.38 | 4.85 | 18.13 |
| | Diluted EPS (in Rs.Not annualised) | 1.18 | 1.54 | 8.74 | 3.35 | 4.82 | 17.99 |
| 17 | Public Shareholding | | | | | | |
| | - Number of Equity Shares | 31,555,667 | 31,655,667 | 31,555,667 | 31,555,667 | 31,655,667 | 31,555,667 |
| | - Percentage of Shareholding | 39.10 | 39.23 | 39.10 | 39.10 | 39.23 | 39.10 |
| 18 | Promoters and promoter group Shareholding | | | | | | |
| | a) Pledged/Encumbered | | | | | | |
| | - Number of Equity Shares | 2,500,000 | 5,200,000 | 2,500,000 | 2,500,000 | 5,200,000 | 2,500,000 |
| | - Percentage of Shares (as a % of the total shareholding of promoter & promoter group) | 5.09% | 10.60% | 5.09% | 5.09% | 10.60% | 5.09% |
| | - Percentage of Shares (as a % of the total share capital of the company) | 3.10% | 6.44% | 3.10% | 3.10% | 6.44% | 3.10% |
| | b) Non-encumbered | - | - | - | - | - | - |
| | - Number of Equity Shares | 46,641,469 | 43,841,469 | 46,641,469 | 46,641,469 | 43,841,469 | 46,641,469 |
| | - Percentage of Shares (as a % of the total shareholding of promoter & promoter group) | 94.91% | 89.40% | 94.91% | 94.91% | 89.40% | 94.91% |
| | - Percentage of Shares (as a % of the total share capital of the company) | 57.80% | 54.33% | 57.80% | 57.80% | 54.33% | 57.80% |

Segment wise Revenue ,Result and Capital Employed

| Sr. No | PARTICULARS | For the quarter ended | Corresponding 3 months ended in the previous year | For the Year ended 31 | For the quarter ended | Corresponding 3 months ended in the previous year | For the Year ended 31- |
|----------|--|-----------------------|---|-----------------------|-----------------------|---|------------------------|
| | | 30-06-2010 | 30-06-2009 | 03-2010 | 30-06-2010 | 06-2009 | 03-2010 |
| | | Unaudited | Unaudited | Audited | Unaudited | Unaudited | Audited |
| 1 | Segment Revenue | | | | | | |
| | (a) CRAMS | 4,747.84 | 5,341.05 | 25,701.86 | 14,268.98 | 16,835.14 | 66,293.81 |
| | (b) Marketable Molecules (MM) | 2,353.59 | 2,002.66 | 9,559.03 | 5,919.44 | 5,936.33 | 25,241.93 |
| | (c) Others | - | - | - | - | - | - |
| | Total | 7,101.43 | 7,343.71 | 35,260.88 | 20,188.42 | 22,771.47 | 91,535.74 |
| | Less: Inter-segment Revenue | - | - | - | - | - | - |
| | Net Sales /Income from Operation | 7,101.43 | 7,343.71 | 35,260.88 | 20,188.42 | 22,771.47 | 91,535.74 |
| 2 | Segment Results {(Profit)(+)/(Loss)(-) before tax and interest from each segment} | | | | | | |
| | (a) CRAMS* | 1,333.78 | 1,555.91 | 8,130.38 | 2,698.07 | 3,916.54 | 13,443.99 |
| | (b) Marketable Molecules (MM)* | 256.92 | 320.99 | 1,797.48 | 1,176.42 | 1,499.99 | 3,635.73 |
| | (c) Others | - | - | - | - | - | - |
| | Total | 1,590.69 | 1,876.90 | 9,927.87 | 3,874.51 | 5,416.53 | 17,079.72 |
| | Less: i) Interest | 530.26 | 522.71 | 2,037.18 | 820.32 | 1,035.26 | 3,876.73 |
| | ii) Other un-allocable expenditure net off un-allocable income | - | - | (50.00) | (0.38) | - | (54.80) |
| | Total Profit Before Tax | 1,060.44 | 1,354.19 | 7,940.68 | 3,054.57 | 4,381.27 | 13,257.79 |
| 3 | Capital Employed (Segment Assets-Segment liabilities) | | | | | | |
| | (a) CRAMS | 51,402.34 | 44,771.32 | 51,605.07 | 88,570.53 | 87,147.91 | 86,697.00 |
| | (b) Marketable Molecules (MM) | 12,143.88 | 11,015.63 | 11,398.97 | 23,442.15 | 24,194.83 | 24,968.34 |
| | (c) Others | 51,553.48 | 34,346.19 | 42,827.23 | 53,968.97 | 37,854.99 | 45,284.23 |
| | Total | 115,099.70 | 90,133.14 | 105,831.27 | 165,981.65 | 149,197.73 | 156,949.57 |
| | * Includes Forex (Loss) / Gain | | | | | | |

On behalf of the Board

 Place: Ahmedabad
 Date: 12th August, 2010

 Janmejy R Vyas
 Chairman & Managing Director